Business | Latest & Breaking News on Business | Photos, Videos, Breaking Stories and Articles on Business

you are here: Home News

There is high pricing pressure on manufacturers: DRL
FM's universal healthcare proposal a step in right direction: DRL
TCS biggest wealth creator in 2012-17, Ajanta Pharma the fastest: Wealth Creation Study
Profits from Copaxone generics to help strengthen balance sheet, expansion: Natco CEO
New draft pharma policy will reduce risks like generalisation of mkt: JM Financial
Preparing for GST implementation for past few months: DRL's Chakraborty
Govt needs to be a strong enabler in pharma sector: Experts
Expect US FDA approvals to pick going forward: Dr Reddy's
No scope of US intervention in Indian pharma cos: Wockhardt
Lupin to see approvals after US FDA gives clean chit: Macquarie
Hope to commercialise 4 products acquired from Teva by FY18: DRL
After DRL-Teva, expect more M&A action in pharma: Prabhudas
US FDA issues shouldn't be overbearing factor for pharma: Citi
Regulatory issues discussed in Feb meet with US, Europe: DRL
Indian pharma cos need to step-up safeguards at plants: Handa
20% of Cipla FY17 revenues to come from US: Chirag Talati
Board to consider buyback of equity shares on Feb 17: Dr Reddy's
Pharma cos capable of resolving FDA concern in 12-15 months:IIFL
Pharma cos facing pricing pressure in US: PhillipCap
USFDA warning: Have 15 days to respond, says DRL CFO
Elepsia drug more relevant to Sun Pharma: Phillipcap
Plan to revamp systems as per FDA expectations: Dr Reddy's
Eye significant growth in acquired UCB drugs: Dr Reddy's
See Rs 400cr increase in top line over next few yrs: Hetero
Core generics, API biz to drive FY16 growth: Dr Reddy's

English

Markets

News

Personal Finance

Mutual Funds

Commodities

Media

Invest Now

Specials

There is high pricing pressure on manufacturers: DRL

FM's universal healthcare proposal a step in right direction: DRL

TCS biggest wealth creator in 2012-17, Ajanta Pharma the fastest: Wealth Creation Study

Profits from Copaxone generics to help strengthen balance sheet, expansion: Natco CEO

New draft pharma policy will reduce risks like generalisation of mkt: JM Financial

Preparing for GST implementation for past few months: DRL's Chakraborty

Govt needs to be a strong enabler in pharma sector: Experts

Expect US FDA approvals to pick going forward: Dr Reddy's

No scope of US intervention in Indian pharma cos: Wockhardt

Lupin to see approvals after US FDA gives clean chit: Macquarie

Hope to commercialise 4 products acquired from Teva by FY18: DRL

After DRL-Teva, expect more M&A action in pharma: Prabhudas

US FDA issues shouldn't be overbearing factor for pharma: Citi

Regulatory issues discussed in Feb meet with US, Europe: DRL

Indian pharma cos need to step-up safeguards at plants: Handa

20% of Cipla FY17 revenues to come from US: Chirag Talati

Board to consider buyback of equity shares on Feb 17: Dr Reddy's

Pharma cos capable of resolving FDA concern in 12-15 months:IIFL

Pharma cos facing pricing pressure in US: PhillipCap

USFDA warning: Have 15 days to respond, says DRL CFO

Elepsia drug more relevant to Sun Pharma: Phillipcap

Plan to revamp systems as per FDA expectations: Dr Reddy's

Eye significant growth in acquired UCB drugs: Dr Reddy's

See Rs 400cr increase in top line over next few yrs: Hetero

Core generics, API biz to drive FY16 growth: Dr Reddy's